Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Astrocytoma 2Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Thrombocytosis 1Sarcoma, Ewing 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Oligodendroglioma 1Neoplasms, Neuroepithelial 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

palbociclib 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × HER2-positive Metastatic Breast Cancer × palbociclib × Clear all
NCT04778982 2023-07-17

Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated
4 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡